Towards efficient early warning: Pathobiology of African swine fever virus “Belgium 2018/1” in domestic pigs of different age classes

Jutta Pikalo1, Marie-Eve Schoder2, Julia Sehl-Ewert1, Angele Breithaupt1, Ann Brigitte Cay2, Coline Lhoëst2, Willem van Campe2, Laurent Mostin2, Paul Deutschmann1, Hanna Roszyk1, Martin Beer1, Sandra Blome1*, Marylène Tignon2*

1 Friedrich-Loeffler-Institut, Suedufer 10, 17493 Greifswald – Insel Riems, Germany; Jutta.Pikalo@fli.de (J.P.); Paul.Deutschmann@fli.de (P.D.); Hanna.Roszyk@fli.de (H.R.); Julia.Sehl@fli.de (J.S.); Angele.Breithaupt@fli.de (A.B.); Martin.Beer@fli.de (M.B.); Sandra.Blome@fli.de (S.B.)

2 Sciensano, Groeselenberg 99, 1180 Brussels, Belgium – Marylène.Tignon@sciensano.be (M.T.); Marie-Eve.Schoder@sciensano.be (M.-E.S.); Coline.Lhoest@sciensano.be (C.L.); Willem.VanCampe@sciensano.be (W.V.); Laurent.Mostin@sciensano.be (L.M.); AnnBrigitte.Cay@sciensano.be (A.C.)

* Correspondence: Sandra.Blome@fli.de (S.B.) and Marylène.Tignon@sciensano.be (M.T.)

Simple Summary: African swine fever (ASF) is a devastating viral disease of both wild boar and domestic pigs. Historically, the disease was mainly found in Sub-Saharan Africa. However, after the introduction of ASF into Georgia in 2007, the fatal disease spread to many European and Asian countries. In the absence of vaccines or treatment options, early detection of disease incursions is of paramount importance to limit the impact on animal health and pig industry. Thus, the biological characteristics of circulating virus strains must be known and communicated to practitioners and official veterinarians. Along these lines, the ASFV strain found in Belgium in 2018 was further characterized for its disease course in young and subadult domestic pigs. In general, clinical and pathological findings were in line with previous experiments utilizing highly virulent ASF genotype II viruses. However, in one of our experimental infections, four out of eight subadult domestic pigs showed milder signs and recovered, which was unexpected and points to an age dependency of clinical signs that could impact on the early recognition of ASF incursions. We hope that communication of the available data will help practical and official veterinarians in the field to detect ASF as early as possible and thus minimize its impact.

Abstract: African swine fever (ASF) is one of the most important and devastating viral diseases in wild boar and domestic pigs worldwide. In the absence of vaccines or treatment options, early clinical detection is key and requires sound knowledge of disease characteristics. To provide practitioners and state veterinarians with detailed information, the objective of the present study was to characterize the ASF virus (ASFV) isolate “Belgium 2018/1” in subadult and weaning domestic pigs. To this end, two animal trials were performed. Trial A included eight subadult domestic pigs and trial B five weaner pigs. In general, clinical signs and pathological lesions were in line with previous studies utilizing highly virulent ASF genotype II viruses. However, in trial A, four subadult domestic pigs survived and recovered pointing to an age dependent outcome. The
long-term fate of those survivors remains under discussion and would need further investigations.

**Keywords:** African swine fever virus, Belgium, virulence, clinical course, domestic pigs

1. **Introduction**

African swine fever (ASF) is a highly contagious and devastating disease of *Suidae*. The causative agent, African swine fever virus (ASFV), is a large double-stranded DNA virus, which belongs to the genus *Asfivirus* in the *Asfarviridae* family [1].

African swine fever has been endemic in many Sub-Saharan African countries and in Sardinia for many decades. However, after the introduction into Georgia in 2007, the disease spread to numerous eastern European countries and reached the European Union (EU) in 2014 with the first outbreaks in wild boar in the Baltic States and Poland [1, 2]. In September 2018, the first case of ASF in wild boar was documented in Belgium [3]. The ASFV isolate associated with this outbreak, “Belgium 2018/1” [1, 4], belongs to p72 genotype II and has shown high virulence in European wild boar [5]. Thus, it was comparable to other genotype II strains that circulate in Europe and Asia showing almost 100% lethality in animals of all age classes and sexes [6]. Clinical signs associated with such an infection include high fever, depression, inappetence, and respiratory distress [2, 7]. Under experimental conditions, the animals showed the first clinical signs starting at 3-5 days post infection (dpi) [6], and animals developing an acute lethal disease course died within 7–13 dpi. Pathomorphological changes included enlarged, haemorrhagic lymph nodes, reddening of tonsils, congestion of spleen or splenomegaly, petechiae in different organs such as the kidney, colon, or urinary bladder, and lung and gall bladder wall edema [7]. Experimentally, the clinical course of ASF has been mostly studied in younger pigs (8-12 weeks), but there are some indications that the clinical course of ASF could be age-dependent under certain conditions [8].

In the absence of vaccines or other treatment options, early clinical detection is of paramount importance and requires detailed knowledge of clinical signs and pathological changes. Thus, biological strain characterization is important to inform farmers, practitioners, and state veterinarians involved in disease control [9].

Here, we report on the experimental inoculation of eight subadult domestic pigs and five weaner pigs for further characterization of the ASFV strain “Belgium 2018/1” and assessment of the influence of age on the clinical course and survival rate.

2. **Materials and Methods**

2.1 **Experimental design**

The study comprised two animal experiments (trials A and B), that were performed to assess virulence and pathogenesis of the genotype II ASFV from Belgium (ASFV strain “Belgium 2018/1”), and to collect suitable reference materials. Trial A was performed at Sciensano, Brussels,
2.2 Animal trials

Trial A

The study comprised eight ASFV and ASFV antibody negative domestic pigs (Hypor hybrid x Pietrain breed) from a conventional farm weighing about 20 kg (10 weeks old). They were housed in a group at Sciensano in Animal Safety Level 3 facilities on slatted floors with water and food ad libitum for the duration of the experiment. The experiment has been authorised by the Ethical Commission of Sciensano under N°20190614-01 and approved by the Biosafety commission. At arrival, the animals were randomly marked with ear tags starting from 1 to 8.

As these animals were part of another test trial, after one week acclimation, each animal received an intramuscular injection of 1 ml of saline solution (mock injection). A second mock administration was performed in the same manner 23 days after the first injection.

At 49 days post mock injection and day 0 for this experiment, the subadult animals (18 weeks of age, weighing between 60 and 80 kg) were inoculated nasally using a small nebulizer (1-mm spray opening) fixed on a syringe to drip the infectious dose into the nostrils. Each animal has received 4 ml virus suspension (2 ml per nostril) containing $1 \times 10^{4.3}$ haemadsorbing units (HAU)/ml of ASFV “Belgium 2018/1”. The inoculum has been cultivated on PBMC following standard procedures (EURL protocol). Following the initial protocol that was drafted assuming acute disease courses, the experiment was terminated at 18 dpi. Due to the lack of high containment capacities and organisational reasons, the study could not be extended beyond 18 dpi.

Upon inoculation, body temperature and clinical parameters of all animals were assessed daily based on a harmonized scoring system as previously described [2]. Evaluated parameters are anorexia, recumbence, skin haemorrhage/cyanosis, swelling, breathing/coughing, ocular discharge, digestive trouble and temperature. The sum of points was recorded as the clinical score (CS). Temperature higher than 40.5°C was considered as severe fever whereas temperature higher than 39.7°C (average +3SD) was considered as mild fever. Animals reaching the humane endpoint of three subsequent days with severe fever (>40.5°C), 9 score points or that were suffering unacceptably without reaching the endpoint score were euthanized by electrocution and exsanguination.

Blood and serum samples were collected prior to inoculation, 3, 7, 10, 14 and 18 dpi at the day of euthanasia. Necropsy was performed on all animals, and at the same time, tissue samples (lymph nodes, spleen, tonsil, lung, liver and kidney) and blood (EDTA, serum) were collected.

Trial B

The study comprised five ASFV and ASFV antibody negative domestic weaner pigs (German Landrace x Large White) from a conventional farm weighing 20 to 25 kg. They were kept in the high containment facility (L3+) of the FLI. The animal experiment was approved by the competent authority (Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei (LALLF) Mecklenburg-Vorpommern, Rostock, Germany) under reference number LALLF 7221.3-2-011/19. Upon arrival, all animals were individually ear-tagged with numbers starting from 16 to 20. Over the course of the trial, the Belgium and trial B was carried out at the Friedrich-Loeffler-Institut (FLI), Greifswald Insel-Riems, Germany.
animals were fed a commercial pig feed with hay cob supplement and had access to water *ad libitum*. The animals were kept in one group and received species specific stable enrichment.

After an acclimatization phase, the animals were inoculated oro-nasally with 2 ml virus suspension containing $2 \times 10^{4.6}$ HAU/ml ASFV “Belgium 2018/1”. The experiment was carried out until 9 days post-infection, when all animals had reached the humane endpoint as defined above. Upon inoculation, clinical scoring was performed as described for trial A. The same endpoint definitions were applied. Animals reaching the humane endpoint were euthanized through intracardial injection of etbutramide (T61, Merck, Darmstadt, Germany) after deep sedation with tiletamine/zolazepam (Zoletil®, Virbac, Carros, France), ketamine (Ketamin 10%, Medistar, Ascheberg, Germany) and xylazin (Xylavet® 20mg/ml, CP-Pharma, Burgdorf, Germany) or ketamine (Ketamin 10%, Medistar, Ascheberg, Germany) and azaperon (Stresnil™ 40mg/ml, Elanco, Bad Homburg, Germany). Blood samples were collected prior to inoculation and at the day of euthanasia. At necropsy tissue samples (lymph nodes, spleen, tonsil, lung, liver and kidney) and blood (EDTA, serum) were collected from all animals.

2.3 Virus inoculum

**Trial A**

The inoculum, ASFV “Belgium 2018/1”, was isolated by the Belgian national reference laboratory (NRL) for ASF at Sciensano from a wild boar carcass found in the Belgian municipality Etalle (Luxembourg region) [3]. The isolate belongs to genotype II and is closely related to strains circulating in Eastern Europe [4] and beyond.

For the animal trial, cell culture supernatant was prepared on porcine peripheral blood monocytic cells (PBMCs) with a final titre of approximately $1 \times 10^{4.3}$ HAU/ml. The titre was confirmed by an end-point back titration of the inoculum and calculated using the Reed and Muench method [10]. Titres were expressed as the amount of virus causing haemadsorption in 50% of infected cultures (HAU/ml).

**Trial B**

The inoculum, ASFV “Belgium 2018/1”, was shipped from the Belgian NRL for ASF at Sciensano to the NRL for ASF in Germany at the FLI. For the animal trial B, culture supernatant was prepared with a final titre of approximately $1 \times 10^{4.6}$ HAU/ml. The titre was confirmed by an end-point back titration of the inoculum and calculated as described in trial A.

2.4 Cells for virus titration

**Trial A**

All virus titrations and haemadsorption tests were carried out using PBMC-derived macrophages according to the protocol of the European Union Reference Laboratory for ASF in which harvesting of the PBMC by buffy coat has been replaced by separation on SepMate™ PBMC Isolation Tubes (STEMCELL Technologies, Vancouver, Canada) with Ficoll-Paque™ PLUS Media (GE Healthcare, Chicago, Illinois, USA).

**Trial B**
All virus titrations and haemadsorption tests were carried out using PBMC-derived macrophages. PBMCs were obtained and treated as previously described [1].

2.5 Pathology

Trial A
Full autopsy was performed on all subadult domestic pigs infected with the ASFV strain „Belgium 2018/1“. Pigs were macroscopically investigated and all lesions documented.

Trial B
Full autopsy was performed on all domestic weaner pigs infected with the ASFV strain „Belgium 2018/1“. Pigs were macroscopically evaluated according to a scoring system published by Galindo-Cardiel et al. [12] with slight modifications [6].

2.6 Processing of samples

Trial A
Serum samples were obtained from native blood through centrifugation at 2,500 g for 20 min at 20°C. Aliquots were stored at -80°C until further use.

Tissue samples were collected during necropsy and stored at -80°C. Fragments of about 100 mg tissue were homogenized in 1 ml phosphate-buffered saline (PBS) with 2 metal beads using a TissueLyser II (Qiagen®GmbH, Hilden, Germany) for 2x2 minutes at 25 Hz before nucleic acid extraction.

Trial B
Serum samples were obtained from native blood through centrifugation at 2,500 g for 20 min. Aliquots were stored at -80°C until further use.

Tissue samples were cut into pea-sized fragments during necropsy and were stored at -80°C for future use. One fragment was homogenized in 1 ml phosphate-buffered saline (PBS) with a metal bead using a TissueLyser II (Qiagen®GmbH, Hilden, Germany) for 3 minutes at 30 Hz before virus isolations (haemadsorption tests) and qPCRs were performed.

2.7 Pathogen detection - nucleic acid extraction and real-time PCR

Trial A
Detection of viral genome was done in blood, serum and tissues employing real-time PCR (qPCR). For qPCR, viral nucleic acids were extracted from blood and serum using the IndiMag Pathogen Kit (Indical Bioscience, Leipzig, Germany) on the Indimag48® extraction platform (Indical Bioscience, Leipzig, Germany) and for tissue, the High Pure Viral Nucleic Acid Kit (Roche Applied Science, Penzberg, Germany) was used. All qPCRs were performed using the primers and probes for ASFV and endogenous gene beta-actin published by Tignon et al. [13] in AgPath-ID™ One-Step RT-PCR Master mix (Applied Biosystems, Foster City, USA) as described in Schoder et al [14]. All PCRs were performed using a LC480® cycler (Roche, Basel, Switzerland). Results of the qPCR were recorded as quantification cycle (Cq) values. Using a dilution series of an
in-house ASFV DNA standard, the genome copies in the respective samples were determined. For generation of the ASFV standard, p72 gene from Lisbon60 strain (genotype 1) was amplified and cloned in pCR2.1 (Invitrogen, Carlsbad, California, USA) for further multiplication in competent E. coli. The plasmid was extracted with Plasmid Plus Maxi Kit (Qiagen, Hilden, Germany) and linearized by restriction with BamHI. Subsequently, the DNA concentration was determined by spectrophotometry using a Nanodrop 2000c (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and the exact number of DNA molecules was calculated using an online tool (http://www.molbiol.edu.ru/eng/scripts/0107.html).

**Trial B**

Prior to real-time PCR analysis, viral nucleic acids from all samples were extracted using the NucleoMag VET kit (Macherey-Nagel, Düren, Germany) on the automated KingFisher 96 flex platform (Thermo Fisher Scientific, Waltham, Massachusetts, USA) according to the manufacturer’s recommendations. Subsequently, nucleic acids were analyzed using the qPCR protocols published by King et al. [15] and Tignon et al. [13] on a BioRad CFX real-time cycler (Bio-Rad Laboratories, Hercules, California, USA). For each qPCR, a quantification cycle (Cq) value was determined. Using a dilution series of the same standard as described in trail A, which was provided by Sciensano (Belgium), the genome copies in the respective samples were determined.

### 2.8 Antibody detection

**Trial A**

Sera were tested in three commercially available antibody ELISAs. In detail, ASFV p72-specific antibodies were detected using the INGEZIM PPA COMPAC ELISA (Ingenasa, Madrid, Spain), the ID Screen ASF competition ELISA (IDVet, Grabels, France) for antibodies against p32 and the ID Screen® African Swine Fever Indirect (IDVet, Grabels, France) for antibodies against p32, p62 and p72. The tests were carried out according to the manufacturer’s instructions.

In addition, serum samples were tested in the indirect immunoperoxidase test according to the standard protocols provided by the European Union Reference Laboratory for ASF with slight modifications regarding the virus strain (Lisbon60 ASFV strain adapted on Vero cells).

**Trial B**

Serum samples were tested as described for trial A. Slight modifications concerned the virus strain used for the indirect immunoperoxidase test (a cell-culture adapted genotype II strain).

### 2.9 Statistical analysis

Initial data recording and analyses (comparison of mean values, transformation of values) were done using Microsoft Excel 2010 (Microsoft Germany GmbH, Munich, Germany).

GraphPad Prism 8 (Graphpad Software Inc., San Diego, CA, USA) was used for graph creation.
3. Results

3.1. Clinical findings

Trial A
Following nasal inoculation, all animals developed unspecific clinical signs starting from day 4 post inoculation (pi) (see Figure 1). The signs included general depression, lack of appetite and unwillingness to stand up, reduced mobility, tremor, reddened skin, cyanosis on the ears and snout, hunched-up back, and respiratory distress. The highest score was reached at 8 and 9 dpi with a maximum of 7 points.

The onset of fever was observed as soon as 4 dpi and the climax of the illness was observed around 8-9 dpi (see Figure 2). The peak of fever was observed at 7 and 8 dpi with the highest number of severe feverish animals. Afterwards the intensity of the fever decreased but remained present under a mild form until 14 dpi. No temperature increase was observed during the infection period for animal #3 despite the presence of other clinical signs. The average number of days with fever was as follows: for severe fever 2.75 +/- 2.25 and for mild fever 5.5 +/-3.85.

Ethical euthanasia was performed between 7 and 14 dpi on animals with clinical scores between 6 and 7 and showing persistent severe fever (3 subsequent days) and/or very poor reactivity. Starting from 12 dpi, the remaining animals started to recover. At the end of the experiment (18 dpi), the surviving pigs, four out of eight, presented no more clinical signs.

Trial B
Following oronasal inoculation, all animals developed severe, unspecific clinical signs starting from day five pi (see Figure 1). The signs included general depression, lack of appetite and mobility, hunched-up back, ataxia and respiratory distress. The onset of fever was observed at 5 dpi (see Figure 2). On 9 dpi, all animals reached the humane endpoint except one, which died overnight. The clinical scores ranged from 5.5 up to 11.

The survival curve from both animal trials are presented in Figure 3.

![Clinical score trial A and B](image)

**Figure 1:** Clinical curve of trials A and B compared. In trial A, the maximum score of the animals was a sum of 7 points on 8 and 9 dpi compared to trial B were animals reached scores of up to 11 points on 9 dpi.
Figure 2: Temperature curves of trials A and B compared. In general, subadult animals of trial A showed lower temperatures compared to the weaner group of trial B. The maximum temperature recorded in trial A was 41.2°C at 7 dpi. In trial B, the highest temperature was 41.7°C at 8 dpi.

Figure 3: Survival curve from both animal trials. In trial A, four out of eight pigs survived until the end of the experiment at 18 dpi. In trial B, all animals were euthanized by 9 dpi (reaching the humane endpoint). One animal died spontaneously in the night from 8 to 9 dpi.

3.2. Pathomorphological findings

Trial A

Animals were euthanized either during the experiment for ethical reason (severe fever for more than 3 consecutive days or high clinical score or poor health condition) or at the end of the experiment (18 dpi). At necropsy, various pathological patterns were observed: from asymptomatic to typical ASF lesions of varying severity: generalized haemorrhagic lymphadenopathy especially of the gastrohepatic lymph nodes, congestion of the spleen, and multiple haemorrhages in several organs, particularly in the kidneys (Table 1).

Table 1: Overview from pathological findings per animal from trial A.
Trial B

Five ASFV “Belgium 2018/1” infected domestic pigs reached the humane endpoint at 9 dpi (n=4) or died spontaneously (n=1), respectively, and were submitted to necropsy. At gross pathologic investigation, all infected pigs revealed typical lesions indicative for ASF. All pigs showed up to severely hemorrhagic enlarged lymph nodes with the gastrohepatic and renal lymph nodes mainly affected. Renal petechiae were present in all pigs and were mainly confined to the renal cortex and to a lesser extent to the medulla. Four out of five pigs had ascites. Marked sanguineous effusion was present in two pigs, while the other two showed accumulation of serous fluid. Likewise, rather mild, serous to sanguineous pleural effusion was present in three animals. Bruises of variable size appeared in four pigs. In individual cases, mild to moderate perirenal and gall bladder wall edema, mucosal petechiae in the urinary bladder, bilateral cyanosis of the ears and rather mild multifocal pulmonary consolidation as well as alveolar oedema were observed (Table 2).

Table 2: Overview from pathological findings per animal from trial B.

<table>
<thead>
<tr>
<th>Animal</th>
<th>Day of euthanasia</th>
<th>Cause</th>
<th>Major pathological observations</th>
</tr>
</thead>
</table>
| 16     | 9 dpi             | humane endpoint | ▪ Multiple bruises  
▪ Pulmonary consolidation  
▪ Hydroperitoneum  
▪ Renal petechiae  
▪ Enlarged, hemorrhagic lymph nodes |
| 17     | 9 dpi             | died acutely over night | ▪ Single bruise  
▪ Subcutaneous hematoma on chest  
▪ Pulmonary alveolar edema |
Renal petechiae
Enlarged, hemorrhagic lymph nodes
Cyanosis of ears
Hydrothorax
Hydroperitoneum
Pulmonary consolidation
Renal petechiae
Mucosal petechiae in urinary bladder
Enlarged, hemorrhagic lymph nodes

18 9 dpi humane endpoint

Cyanosis of ears
Multifocal bruises
Hemothorax
Hemoperitoneum
Perirenal edema
Renal petechiae
Enlarged, hemorrhagic lymph nodes

19 9 dpi humane endpoint

Single bruise
Hydrothorax
Pulmonary consolidation
Hemoperitoneum
Gall bladder wall edema
Renal petechiae
Enlarged, hemorrhagic lymph nodes

20 9 dpi humane endpoint

3.3 Pathogen detection

Trial A

Prior to infection, all animals were tested negative for ASFV nucleic acids by qPCR in blood samples. After infection, the presence of the virus was first detected in blood samples of 3 animals collected at 3 dpi. All the remaining animals were detected ASFV PCR positive at the following sampling time point (7 dpi), except one animal (# 3) which became positive 10 dpi. Once detected positive, the animals remain positive until death by ethical euthanasia or at the end of the experiment (18 dpi).

When detected at 3 dpi, the virus load was low (<25 copies/run). However, at 7 dpi and until 14 dpi, the virus load in blood was at a maximum with 1.29E3 to 6.8E4 copies/reaction (Table 3).

| Table 3: Trial A: Real-time PCR results of blood from 0 to 18 dpi. | Genome detection in blood is presented as genome copies per reaction (5 µl). ND: due to technical and organisational problems samples could not be taken and analysed. |

<table>
<thead>
<tr>
<th>Animal</th>
<th>0 dpi</th>
<th>3 dpi</th>
<th>7 dpi</th>
<th>10 dpi</th>
<th>14 dpi</th>
<th>18 dpi</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.00E+00</td>
<td>2.92E-01</td>
<td>2.92E+04</td>
<td>ND</td>
<td>4.26E+03</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>0.00E+00</td>
<td>0.00E+00</td>
<td>1.27E+03</td>
<td>ND</td>
<td>4.26E+03</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>0.00E+00</td>
<td>0.00E+00</td>
<td>0.00E+00</td>
<td>1.90E+01</td>
<td>1.55E+01</td>
<td>7.85E+00</td>
</tr>
<tr>
<td>4</td>
<td>0.00E+00</td>
<td>6.70E-01</td>
<td>1.51E+04</td>
<td>ND</td>
<td>4.26E+03</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>0.00E+00</td>
<td>0.00E+00</td>
<td>2.02E+02</td>
<td>1.29E+03</td>
<td>3.53E+02</td>
<td>2.84E+02</td>
</tr>
<tr>
<td>6</td>
<td>0.00E+00</td>
<td>2.23E+01</td>
<td>6.80E+04</td>
<td>ND</td>
<td>4.26E+03</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>0.00E+00</td>
<td>0.00E+00</td>
<td>4.01E+02</td>
<td>1.66E+03</td>
<td>5.25E+02</td>
<td>1.27E+02</td>
</tr>
<tr>
<td>8</td>
<td>0.00E+00</td>
<td>0.00E+00</td>
<td>2.81E+03</td>
<td>4.05E+03</td>
<td>8.70E+02</td>
<td>1.97E+01</td>
</tr>
</tbody>
</table>
At the end of the trial, viral genome was detected in blood, serum and all tissue samples (spleen, lung, lymph nodes, tonsil, kidney and liver). Highest loads of viral genomes (>1E3-1E4 copies/reaction) were found in blood, serum and tissues from animals presenting severe clinical signs whereas low viral genome loads (<5E2 copies/reaction) were detected in the blood of animals that survived the infection (Table 4).

Table 4: Trial A: Real-time PCR results of blood, serum and organ samples at the day of euthanasia. Genome detection in blood, serum and organs are presented as genome copies per reaction (5 µl).

<table>
<thead>
<tr>
<th>Animal</th>
<th>Day of euthanasia</th>
<th>Blood</th>
<th>Serum</th>
<th>Spleen</th>
<th>Tonsil</th>
<th>Lymph node</th>
<th>Lung</th>
<th>Liver</th>
<th>Kidney</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7 dpi</td>
<td>2.92E+04</td>
<td>1.14E+03</td>
<td>3.71E+04</td>
<td>2.10E+04</td>
<td>3.33E+04</td>
<td>2.01E+04</td>
<td>1.32E+04</td>
<td>7.34E+02</td>
</tr>
<tr>
<td>2</td>
<td>14 dpi</td>
<td>4.26E+03</td>
<td>5.95E+02</td>
<td>4.52E+03</td>
<td>8.55E+02</td>
<td>6.61E+03</td>
<td>8.20E+02</td>
<td>2.63E+03</td>
<td>1.20E+02</td>
</tr>
<tr>
<td>3</td>
<td>18 dpi</td>
<td>7.85E+00</td>
<td>0.00E+00</td>
<td>3.70E+00</td>
<td>5.72E+01</td>
<td>4.31E+01</td>
<td>4.79E+02</td>
<td>1.73E+00</td>
<td>1.45E+00</td>
</tr>
<tr>
<td>4</td>
<td>8 dpi</td>
<td>1.51E+04</td>
<td>1.00E+03</td>
<td>1.87E+04</td>
<td>1.51E+04</td>
<td>8.76E+03</td>
<td>9.54E+03</td>
<td>3.06E+04</td>
<td>8.94E+02</td>
</tr>
<tr>
<td>5</td>
<td>18 dpi</td>
<td>2.48E+02</td>
<td>1.75E+01</td>
<td>4.78E+00</td>
<td>5.14E+02</td>
<td>1.32E+02</td>
<td>5.07E+00</td>
<td>0.00E+00</td>
<td>1.52E+00</td>
</tr>
<tr>
<td>6</td>
<td>7 dpi</td>
<td>6.81E+04</td>
<td>1.52E+04</td>
<td>4.31E+04</td>
<td>5.67E+04</td>
<td>3.70E+04</td>
<td>5.96E+04</td>
<td>1.17E+04</td>
<td>1.38E+04</td>
</tr>
<tr>
<td>7</td>
<td>18 dpi</td>
<td>1.27E+02</td>
<td>1.12E+01</td>
<td>3.48E+00</td>
<td>4.23E+02</td>
<td>3.19E+02</td>
<td>8.19E+00</td>
<td>2.40E+00</td>
<td>8.14E+01</td>
</tr>
<tr>
<td>8</td>
<td>18 dpi</td>
<td>1.97E+01</td>
<td>1.79E+02</td>
<td>9.93E+00</td>
<td>1.02E+02</td>
<td>6.81E+00</td>
<td>5.80E+00</td>
<td>4.23E+00</td>
<td>2.85E+00</td>
</tr>
</tbody>
</table>

Trial B

Prior to inoculation, all animals were tested negative for ASFV, ASFV antigen, and viral nucleic acids.

At the end of the trial, viral genome was detected in blood and all tissue samples (spleen, lung, lymph nodes, tonsil, kidney and liver). Highest loads of viral genome were found especially in blood, serum and spleen (Table 5).

Table 5: Trial B: Real-time PCR results of blood, serum and organ samples at the day of euthanasia. Genome detection in blood, serum and organs are presented as genome copies per run (5 µl).

<table>
<thead>
<tr>
<th>Animal</th>
<th>Day of euthanasia</th>
<th>Blood</th>
<th>Serum</th>
<th>Spleen</th>
<th>Tonsil</th>
<th>Lymph node</th>
<th>Lung</th>
<th>Liver</th>
<th>Kidney</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>9 dpi</td>
<td>1.02E+04</td>
<td>2.32E+03</td>
<td>4.51E+03</td>
<td>1.64E+03</td>
<td>4.23E+01</td>
<td>1.22E+02</td>
<td>3.59E+02</td>
<td>4.94E+01</td>
</tr>
<tr>
<td>17</td>
<td>9 dpi</td>
<td>3.64E+04</td>
<td>1.58E+04</td>
<td>1.54E+04</td>
<td>8.56E+03</td>
<td>9.77E+05</td>
<td>4.52E+03</td>
<td>4.68E+04</td>
<td>3.78E+03</td>
</tr>
<tr>
<td>18</td>
<td>9 dpi</td>
<td>1.01E+05</td>
<td>2.25E+04</td>
<td>1.40E+04</td>
<td>1.90E+03</td>
<td>5.89E+02</td>
<td>5.81E+03</td>
<td>2.20E+04</td>
<td>7.07E+02</td>
</tr>
<tr>
<td>19</td>
<td>9 dpi</td>
<td>6.19E+04</td>
<td>1.39E+04</td>
<td>4.61E+03</td>
<td>3.36E+03</td>
<td>5.87E+02</td>
<td>5.52E+02</td>
<td>4.04E+03</td>
<td>5.00E+02</td>
</tr>
<tr>
<td>20</td>
<td>9 dpi</td>
<td>7.83E+04</td>
<td>2.71E+04</td>
<td>2.30E+04</td>
<td>1.89E+04</td>
<td>3.12E+03</td>
<td>3.68E+03</td>
<td>1.10E+04</td>
<td>9.87E+02</td>
</tr>
</tbody>
</table>

3.4 Antibody detection

Trial A

Prior to inoculation, all animals were tested negative for ASFV antibodies (Ab) by ELISA tests.

After infection, seroconversion against ASFV p72 was demonstrated using the INGEZIM PPA COMPAC ELISA (Ingenasa, Madrid, Spain) in the five still remaining animals at 10 dpi (two positive and three doubtful results) (Figure 4). With the ID Screen ASF Competition ELISA (IDVet, Grabels, France), which detects p32, all remaining animals were positive from 10 dpi, except one which already showed a questionable result on 7 dpi. By testing with the ID Screen ASF Indirect ELISA (IDVet, Grabels, France) three animals showed a questionable result on 10 dpi, one was negative and one showed a positive antibody result from 10 dpi onwards.

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 2 August 2021
From 14 dpi and onwards, all the four remaining animals were seropositive in all three ELISA assays.

With the indirect immunoperoxidase test seroconversion was observed starting from 7 dpi. At the end of the experiment (18 dpi), the surviving animals presented antibody titres between 2560 and 5120.

Trial B

No antibodies were detected in the sera prior to inoculation or at the end of the trial on 9 dpi with all ELISAs (Figure 4). With the indirect immunoperoxidase test the animals showed antibody titres between 160 and 620 at 9 dpi.

Figure 4: Seroconversion of the subadult animals from trial A detected on 10 dpi with INGEZIM PPA COMPAC ELISA (Ingenasa, Madrid, Spain). Weaner pigs from trial B showed no ELISA detectible seroconversion at 9 dpi. The ELISA cutoff is 50% blocking which is indicated as a dotted line in both graphs.

4. Discussion

African swine fever virus has entered the European Union and many countries in Eastern Europe and Asia, threatening animal health and agriculture alike. In the absence of a licensed vaccine or other effective treatment options, prevention through farm biosafety and the earliest possible detection of outbreaks are of utmost importance. Early detection is only assured if clinical signs are promptly recognized and correctly interpreted by farmers and practitioners. Thus, well-trained livestock farmers and veterinarians in practice and subsequently the competent authorities play a crucial role here. Basic data to inform these key persons can be obtained from animal experimental work, such as that carried out in the NRLs as part of their tasks. These studies are not infrequently conducted to generate and archive relevant and well-characterized sample materials for validation and harmonization of diagnostic methods at the national level (Regulation (EU) 2017/625, Article 101), but provide space to map issues of pathogenesis and virulence of locally relevant viral variants. In this context, the present study was conducted in close cooperation of the Belgian and the German NRLs with the aim to further characterize the ASF virus isolate “Belgium 2018/1” in domestic pigs. Thereby, focus was laid on the clinical courses and pathomorphological changes in different age classes of animals. While various studies with genotype II strains have been conducted in weaner pigs, studies with older animals are scarce. Though there are indications that no age
dependency is involved in highly virulent strains [16], different courses have been described for moderately virulent strains [8]. In the study published by Post et al. [8], age had a marked effect on disease outcome while inoculation dose was secondary. The latter is consistent with studies describing similar, often lethal, courses with different doses of highly virulent virus strains [11].

In our combined study, inoculation of weaner pigs did not hold any surprise. After an incubation period of five days, which is in line with previous findings [17, 18], all young animals developed an acute lethal disease course with high fever, general depression, anorexia, ataxia, and respiratory distress. All animals reached the humane endpoint or had acutely died by 9 dpi. It is noteworthy, that again, the clinical signs were severe but rather unspecific leading to many differential diagnoses that could be relevant in the field. Necropsy findings were in line with previous studies using ASFV “Armenia” [6]. Viral genome was found in organs, blood and serum of all animals irrespective of the disease course. In line with previous studies, blood, spleen and liver showed highest copy numbers in the majority of animals. However, genome loads reflected the clinical course and timepoint of sampling. While viral genome loads in spleen were roughly 10,000 genome copies per run for animals sampled between days 7 and 9, less than 10 genome copies were found in recovering pigs at 18 dpi.

The inoculation of the older pigs took a different, rather unexpected turn. Although the Belgian virus hardly differs at the sequence level from Armenia and Georgia [4], which showed rather age-independent courses in previous studies [16], only a 50% lethality was recorded in the present study until the end of the experiment at 18 dpi. Clinical signs were milder and pathomorphological findings reflected the clinical course (severe to absent lesions). It has to be mentioned, however, that the capacity-related observation period of 18 days limits a reliable and complete statement on the final clinical outcome. Previous studies have shown intermittent and recurring viremia after 18 dpi [2]. In addition, it cannot be excluded from the clinical scoring and virus detection, that at least one animal (# 3) got infected only by contact and thus slightly delayed. Nevertheless, the lack of findings in the pathological-anatomical examinations and low genome loads in organs indicate that the remaining animals were true survivors or showed only a sub-clinical infection due to the lack of lesions. Survivors were rarely seen when using highly virulent ASFV strains of genotype II, however, they were reported. As an example, Gallardo et al. [2] reported on the survival of one out of eight pigs intramuscularly inoculated with the Lithuanian ASFV strain “LT14/1490”. The respective pig showed weak and intermittent peaks of viremia, and viral DNA could be detected in tissues at 38 dpi. However, no seroconversion was observed which was different in our study where all survivors seroconverted. Animals surviving the acute phase were also reported by Walczak et al. [9]. In this study, two animals inoculated with the Polish ASFV “Pol18_28298_O111” strain (pig one got 1000 HAU and pig two got 500 HAU) developed chronic disease courses after a delayed incubation period (pig one 12 dpi: clearly visible clinical signs, like joint swelling and minor breathing disorders, moderate fever and constant low virus load value in blood but without pathological lesions. Pig two 20 dpi: showed only moderate fever and enlarged submandibular lymphnodes) but had to be euthanized 24 and 32 dpi, respectively. While it is obvious, that animals may survive, long-term fate
and epidemiological role of those survivors is still controversially discussed and needs further long-term studies to allow final conclusions.

Apart from age, application route and dose, the general health and immune status, genetic background (hybrid breed) and concomitant infections could impact on the clinical outcome and thus explain our observations. Indeed, due to the size of the subadult pigs, inoculation had to happen in standing position rather than in dorsal recumbency that was used for the weaner pigs. This could have influenced the amount of virus that reached the tonsils. Adding to that, the dose is reduced when compared to body weight. However, as mentioned earlier, several studies showed severe courses upon low-dose infection and did not report a significant impact of the viral dose on the final outcome [2, 9, 11]. Whether an even lower dose would have led to more survivors or just less infected pigs could be debated. Considering the study reported by Pietschmann et al. [11], we could rather expect lower infection rates. The route itself can also play a role in the efficiency of infection. While trial A was conducted with nasal inoculation, trial B was done with oro-nasal inoculation. In this context, Howey et al. [19] reported on the variable efficiency of intranasopharyngeal (INP) and intraoropharyngeal (IOP) inoculations, especially using lower doses ($10^2$ HAU). In this study, oropharyngeal infection was less efficient. However, infection was confirmed in all animals of our study upon either nasal or oral infection. Given that the full range of clinical outcomes and swift seroconversion in survivors was seen, a dose related impact cannot be excluded but does not seem likely. Considering that both studies employed clinically healthy, commercial pigs, the impact of the general health status seems rather small.

With regard to the genetic background, differences in susceptibility are rather frequently seen in indigenous pig breeds in Africa [20; 21]. Yet, our study involved only widely used pig breeds of Europe that may not differ markedly in their susceptibility even if a different hybrid breed was used in trial A than in trial B. As genotyping of pigs was not carried out, a final conclusion on this aspect cannot be made.

Recently, the gut microbiota was discussed as an important factor for ASF susceptibility. Interestingly, fecal microbiota transplantation from warthogs to domestic pigs resulted in higher resistance of the latter [22]. While we cannot rule out such factors, we do not assume high impact of the gut microbiota in our study.

The variability of clinical signs and outcomes in our study points to both a certain age-dependence and biological variability that has to be taken into account when communicating clinical signs and typical disease outcomes.

5. Conclusions

Taken together, we saw a variable clinical picture when considering all age classes of animals that could cause problems in the clinical evaluation of ASF under field conditions and in early warning scenarios. The final fate of the here observed survivors could not be addressed under the limited time scheme of our study and should be part of further long term studies with older pigs.

The outcome of our study highlights the need for swift and reliable laboratory diagnosis, even when only mild to moderate clinical signs are detected. Easy and fast genome detection by qPCR did not pose any problems even with the surviving animals.
We hope that communication of the available data will help practical and official veterinarians in the field to detect ASF as early as possible and thus minimize its impact. The study outcome clearly underlines once again that clinical courses can be highly variable and non-specific. For this reason, exclusion diagnostics of ASF by sensitive qPCR methods should be routine, especially in light of the current situation with ASF outbreaks in several countries including Germany.


**Funding:** This publication is partly based upon work from COST Action 15116 ASF-STOP supported by the European Cooperation in Science and Technology and was partially funded by the FLI ASF research network. This publication is also partially based on work supported by the Belgian Federal Agency for the Safety of the Food Chain (FASFC).

**Institutional Review Board Statement:** In the animal experiment, all applicable animal welfare regulations including EU Directive 2010/63/EC were taken into consideration. The animal experiment was externally approved by the competent authority (Landesamt für Landwirtschaft, Lebensmittelsicherheit und Fischerei (LALLF) Mecklenburg-Vorpommern) under reference number 7221.3-2-011/19. Experiment at Sciensano has been authorised by the Ethical Commission of Sciensano under N°20190614-01 and approved by the Biosafety commission.

**Data Availability Statement:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Acknowledgments:** The authors would like to thank all animal caretakers, especially Robert Pelcot, Arnaud Bouquiaux, Matthias Jahn, Steffen Brenz and Dominique Lux for their constant help and support and for excellent lab work Ulrike Kleinert, Robin Brandt, and the team of analysts from ENZOVEB at Sciensano, for excellent assistance and support in the pathology Christian Loth, involved in this study for their excellent work.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**


